Biotech ETFs news and market signals

Takeda Pharmaceutical has secured approval for its drug rusfertide, targeting polycythemia vera, a development that could ripple through specialized biotech and pharmaceutical exchange-traded funds. This regulatory milestone sets the stage for potential short-term shifts in investor sentiment and capital flows within the healthcare sector.